Pharmaceutical

VistaGen Therapeutics announced its candidate AV-101 received a Fast Track Designation from the FDA.

VistaGen Therapeutics (NASDAQ:VTGN) announced its candidate AV-101 received a Fast Track Designation from the US Food and Drug Administration (FDA).
As quoted in the press release:

The FDA’s Fast Track process is designed to facilitate the development and review of new treatments for serious conditions with unmet medical need such as MDD.
“Fast Track Designation is another important regulatory milestone for our AV-101 program for MDD, providing us the opportunity for frequent interactions with the FDA focused on the most appropriate and efficient development pathway to bring AV-101 to MDD patients,” said Shawn Singh, Chief Executive Officer of VistaGen. “We are on track to dose the first patient in our AV-101 Phase 2 MDD adjunctive treatment study in the first quarter of 2018.”

Click here to read the full press release.

Source: www.marketwired.com

Featured

MARKETS

Markets
TSX20197.61+15.69
TSXV702.09-3.49
DOW31261.90+8.77
S&P 5003901.36+0.57
NASD11354.62-33.88
ASX7145.60+81.10

COMMODITIES

Commodities
Gold1846.53+0.13
Silver21.75+0.03
Copper4.30+0.02
Palladium1968.65+11.53
Platinum957.67+3.19
Oil110.35-1.86
Heating Oil3.62-0.05
Natural Gas8.06-0.25

DOWNLOAD FREE REPORTS

×